en
Scientific article
Open access
English

"Late" Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn

Published inFrontiers in Pharmacology, vol. 8, 217
Publication date2017
Abstract

We report a case of carbamazepine withdrawal syndrome following in utero exposure to carbamazepine related to a pharmacogenetic predisposition factor. The infant was born at 37 1/7 weeks' gestation by cesarean section to a mother treated for epilepsy with carbamazepine. One hour and thirty minutes after birth, the infant presented a respiratory distress with severe oxygen desaturation requiring intubation 5 h after birth. On the third day of life the infant developed clinical signs of a withdrawal syndrome which resolved progressively after 16 days and symptomatic treatment. The infant genotype analysis showed two low activity CYP2C9 allelic variants ((∗)2/(∗)3 heterozygote) predicting a CYP2C9 slow metabolizer phenotype which could explain reduced carbamazepine elimination and a late and long-lasting withdrawal symptoms observed 3 days after birth. The association of a withdrawal syndrome with carbamazepine exposure has not been previously reported and pharmacogenetic tests might therefore be useful in identifying patients at risk.

Citation (ISO format)
PASSIA, Evangelia et al. ‘Late’ Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn. In: Frontiers in Pharmacology, 2017, vol. 8, p. 217. doi: 10.3389/fphar.2017.00217
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1663-9812
477views
175downloads

Technical informations

Creation2017/10/18 15:46:00
First validation2017/10/18 15:46:00
Update time2023/03/15 02:17:16
Status update2023/03/15 02:17:15
Last indexation2024/01/17 01:14:51
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack